Two consecutive IND applications for biopharmaceuticals have been accepted, and Hausen has a deep layout in biopharmaceuticals

Compared with biopharmaceuticals that are poised for development, Hansen Pharmaceuticals has achieved fruitful results in the field of small molecules
.
With the launch of the first-class new drug Hengmu (imitenofovir tablets), the number of first-class innovative drugs approved by Hansen Pharmaceutical has increased to 5, ranking second among domestic pharmaceutical companies, and there are more than 20 innovative drugs In different clinical stages

In June 2021, Hansen Pharmaceuticals and Osprey Asset Management jointly established Bosheng Pharmaceutical.
Hansen Pharmaceuticals provides preclinical, clinical and commercial support to accelerate the R&D and listing of product pipelines in China; Osprey Asset Management through its Global biomedical resources and portfolio companies support Bosheng Pharmaceutical to introduce innovative products
.

For twenty-six years, Hansen Pharmaceuticals has adhered to patient benefit-centered and clinical data-oriented pharmaceutical services, with the highest goal of patients obtaining better treatment options, and promoting the advancement of clinical medication
.
With Hansen’s independent pharmaceutical research, preclinical research, clinical research and registration application, a complete R&D system has been formed.